Excerpt:
Alexion shareholders asked a Connecticut federal judge to approve a $125 million settlement to end claims that the drugmaker caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light, a deal that comes five months after the investors won certification of their class. [...]
